NCT05381506View on ClinicalTrials.gov

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 31, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
DLBCL
Interventions
DRUG

Orelabrutinib and Gemox

"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"

Trial Locations (8)

Unknown

Chongqing Cancer Hospital, Chongqing

Guangxi Medical University Cancer Hospital, Naning

Hubei Cancer Hospital, Wuhan

Hunan Cancer Hospital, Changsha

West China Hospital.Sichuan University, Chengdu

Tianjin Medical University Cancer Hospital, Tianjin

The Second Affiliated Hospital of Kunming Medical University, Kunming

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER